MedPath

Basal Insulins - Pharmacodynamics

Phase 4
Completed
Conditions
Diabetes
Interventions
Registration Number
NCT00566124
Lead Sponsor
University of Aarhus
Brief Summary

To purpose of this study is to compare the pharmacodynamic properties of insulin detemir, insulin glargine and NPH insulin after a single subcutaneous injection.

Detailed Description

In this randomized, double-blind, euglycemic glucose clamp study, 10 healthy male volunteers received a subcutaneous injection of 0.4 U/kg insulin detemir, insulin glargine or NPH insulin on three separate study days in a cross-over design. After insulin administration, plasma glucose was maintained at 0.3 mmol/l below fasting level for 24 hours by manually adjusted glucose infusion. C-peptide, insulin, NEFA and counter regulatory hormones were measured throughout the clamp period. Endogenous glucose release (EGR) was assessed by the isotope dilution technique (3-3H-glucose).

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
10
Inclusion Criteria
  • Male
  • BMI 20 - 50 kg/m2
  • Blood pressure < 140/90 mmHg
  • signed informed consent
  • Caucasien
Exclusion Criteria
  • Diabetes or other disease
  • Alcohol or drug abuse
  • Smoking
  • Use of prescription drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
1Insulin detemirInsulin detemir
2Insulin glargineInsulin glargine
3InsulatardNPH insulin
Primary Outcome Measures
NameTimeMethod
Area under GIR-curve, maximal glucose infusion rate, time to maximal glucose infusion rate.24 hours
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Medical department M (Endocrinology and Diabetes), Aarhus University Hospital

🇩🇰

Aarhus, DK, Denmark

© Copyright 2025. All Rights Reserved by MedPath